Welcome to our dedicated page for TEVA PHARMACEUTICAL INDUSTRIES SEC filings (Ticker: TEVJF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TEVA PHARMACEUTICAL INDUSTRIES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TEVA PHARMACEUTICAL INDUSTRIES's regulatory disclosures and financial reporting.
Teva Pharmaceutical Industries Limited reported Q2 2026 net revenues of $4,142 million, roughly flat versus $4,176 million a year earlier, but recorded a net loss attributable to Teva of $576 million, compared with net income of $282 million. The loss reflects sharply higher R&D expense of $970 million, including a $724 million in‑process R&D charge from the Emalex Biosciences acquisition, and $230 million of legal settlements and loss contingencies.
For the first six months of 2026, net revenues were $8,124 million and net loss attributable to Teva was $207 million. Operating cash flow was $371 million, while investing activities used $263 million, largely driven by Emalex. At June 30 2026, cash and cash equivalents were $3,655 million, total assets $39,857 million, total equity $7,757 million, short‑term debt $4,500 million and long‑term senior notes and loans $12,092 million. Teva continues to classify its API business as held for sale, with $1,794 million of related assets and $313 million of liabilities, and maintains a $4,854 million provision for legal settlements and loss contingencies related to ongoing matters.
Teva Pharmaceutical Industries reported Q2 2026 net revenues of $4.14 billion, down 1% year over year, as lower U.S. generics, especially lenalidomide, offset strong growth in key innovative brands. AUSTEDO, AJOVY and UZEDY together generated over $1 billion, growing 43% in local currency.
Teva recorded a GAAP net loss of $576 million, or $0.49 per share, driven by $724 million of acquired IPR&D and $2 million of operating expenses from the $700 million Emalex Biosciences acquisition. Non‑GAAP net income was $21 million with diluted EPS of $0.02; adjusted EBITDA was $474 million versus $1.23 billion a year earlier.
Operating cash flow improved to $411 million and free cash flow to $622 million. For 2026, Teva maintains guidance for revenues of $16.5–$16.85 billion, non‑GAAP EPS of $1.91–$2.11 and free cash flow of $2.0–$2.4 billion, while raising its outlook for AUSTEDO, AJOVY and UZEDY to about $3.7 billion combined. The company also plans to replace its ADS program with a direct NYSE listing of ordinary shares and noted an upgrade of its corporate credit rating to investment grade BBB‑.
Teva Pharmaceutical Industries executive Matthew Shields, EVP of Global Operations, reported an open-market sale of 9,989 Ordinary Shares. The shares were sold at an average price of $32.1901 per share, and his directly held Ordinary Share position is reported as 0 shares following the transaction. The filing notes that the Ordinary Shares may be represented by American Depositary Shares, each currently representing one Ordinary Share.
TEVA Form 144 notice reports a proposed sale of Ordinary Shares and a recent sale by an affiliated holder. The filing lists a planned disposition through Citigroup Global Markets and records a sale by Matthew Shields of 16,195 shares for $532,329.65 on 06/03/2026. The securities are identified as Ordinary Shares with an associated identifier 9989.
Teva Pharmaceutical Industries EVP and CFO Eliyahu Sharon Kalif sold 106,563 Ordinary Shares in an open-market transaction on June 11, 2026 at a weighted average price of $34.0954 per share. After the sale, he directly holds 65,621 Ordinary Shares.
The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2025, indicating it was scheduled in advance. The filing notes that the price reflects a weighted average from multiple trades between $33.985 and $34.25 per share. Each Ordinary Share may also be represented by one American Depositary Share.
Teva Pharmaceutical Industries submitted a Form 144 notice reporting proposed sales of ordinary shares tied to rollover/compensation transactions and prior dispositions. The filing lists multiple lot sizes dated 03/03/2026 and 03/04/2026, including quantities of 24,900, 33,512, and 23,251 shares. The excerpt also shows 153,251 shares sold during the past three months on 05/14/2026 for $5,457,368.64. The filing names Citigroup Global Markets as a broker and identifies the transactions as compensation ordinary shares or shares from rollover.
Teva Pharmaceutical Industries director Sol J. Barer exercised 21,739 restricted share units into ordinary shares. The RSUs were granted on June 5, 2025 and vested on June 5, 2026, resulting in delivery of 21,739 ordinary shares at a stated price of $0.00 per share.
Following this vesting and conversion, Barer directly holds 448,011 ordinary shares. The transaction reflects a compensation-related derivative exercise with no reported open-market buying or selling. The ordinary shares may also be represented by American Depositary Shares, each currently equal to one ordinary share.
Teva Pharmaceutical Industries director Chen Lichtenstein exercised 14,492 restricted share units into ordinary shares, increasing his direct stake to 19,296 shares. The units were granted on June 5, 2025 and vested on June 5, 2026, and each unit settled into one ordinary share at no cash cost to him.
The ordinary shares may be held directly or represented by American Depositary Shares, each currently equal to one ordinary share. The filing reflects a compensation-related equity vesting and exercise, not an open-market purchase or sale.
TEVA Pharmaceutical Industries director Rosemary A. Crane exercised 14,492 restricted share units into ordinary shares. The Form 4 shows she acquired 14,492 ordinary shares on June 5, 2026 through the conversion of vested restricted share units at a stated price of $0.00 per share.
Following this transaction, Crane directly holds 127,739 ordinary shares. The derivative position associated with these 14,492 restricted share units is now fully settled, with no remaining units from this grant. The footnotes state that each restricted share unit represented a contingent right to receive one ordinary share or its cash value and that the units were granted on June 5, 2025 and vested on June 5, 2026.
TEVA PHARMACEUTICAL INDUSTRIES LTD director Amir Elstein exercised restricted share units into ordinary shares. On June 5, 2026, 14,492 restricted share units vested and were converted into 14,492 ordinary shares at a stated price of $0.00 per share.
After this non-cash equity compensation event, Elstein directly held 2,118,455 ordinary shares. Each restricted share unit provided a contingent right to receive one ordinary share or, at the company committee’s option, the cash value of one ordinary share. No open-market buy or sell transaction was reported in this filing.